Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective

Melanie Schroeder,1 Nicole Benjamin,2 Laura Atienza,3 Chandroday Biswas,4 Alan Martin,5 John D Whalen,6 José Luis Izquierdo Alonso,7 Juan Antonio Riesco Miranda,8 Juan José Soler-Cataluña,9 Alicia Huerta,3 Afisi S Ismaila10,11 1Value Evidence and Outcomes, GlaxoSmith...

Full description

Bibliographic Details
Main Authors: Schroeder M, Benjamin N, Atienza L, Biswas C, Martin A, Whalen JD, Izquierdo Alonso JL, Riesco Miranda JA, Soler-Cataluña JJ, Huerta A, Ismaila AS
Format: Article
Language:English
Published: Dove Medical Press 2020-07-01
Series:International Journal of COPD
Subjects:
cost-utility analysis
health-related quality of life
incremental cost-effectiveness ratio
fluticasone furoate
vilanterol
umeclidinium
Online Access:https://www.dovepress.com/cost-effectiveness-analysis-of-a-once-daily-single-inhaler-triple-ther-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/cost-effectiveness-analysis-of-a-once-daily-single-inhaler-triple-ther-peer-reviewed-article-COPD

Similar Items